Log In
Print this Print this

inhaled Lynovex, cysteamine (NM001)

  Manage Alerts
Collapse Summary General Information
Company NovaBiotics Ltd.
DescriptionInhaled dual mucoactive-antibacterial
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationCystic fibrosis (CF)
Indication DetailsTreat cystic fibrosis (CF)
Regulatory Designation U.S. - Orphan Drug (Treat cystic fibrosis (CF));
EU - Orphan Drug (Treat cystic fibrosis (CF))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today